TNF and rheumatoid arthritis: In a few clinical trials, the use of DMARDs, such as tumour necrosis factor-α (TNF-α) inhibitor, has been shown to effectively reduce RA pain during the early phase, but 40%–50% of the patients in a longer duration randomised clinical trial complained of unresolved pain at the end of the study (9, 10).